CYAD - Celyad Oncology presents early-stage data from blood cancer trial for CAR-T therapy

undefined/iStock via Getty Images As per the preliminary data, CYAD-211 shRNA-based allogeneic CAR T candidate developed by Celyad Oncology ([[CYAD]] -3.7%) has indicated a mixed safety profile based on an early-stage trial for patients with relapsed/refractory multiple myeloma (r/r MM). Results presented at the European Hematology Association ((EHA)) 2021 Virtual Congress included safety and tolerability data from six patients who received the first two dose levels (30×106 and 100×106 cells per infusion). The open-label, dose-escalation trial is designed to evaluate multiple dose levels of CYAD-211: 30×106, 100×106, and 300×106 cells per infusion. The first two cohorts did not demonstrate any dose-limiting toxicity ((DLT)), Graft-versus-Host disease (GvHD), or CAR T-cell-related encephalopathy syndrome ((CRES)), Celyad said in a statement. Of the five evaluable patients at the first two dose levels, two patients who were triple therapy exposed achieved a partial response ((PR)). One patient had a stable disease. Patient 1 (dose level

For further details see:

Celyad Oncology presents early-stage data from blood cancer trial for CAR-T therapy